SkinBioTherapeutics Plc
SBTX.L · LSE
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | £4,638 | £1,209 | £132 | £75 |
| % Growth | 283.6% | 815.5% | 76.6% | – |
| Cost of Goods Sold | £1,933 | £526 | £47 | £29 |
| Gross Profit | £2,706 | £683 | £85 | £45 |
| % Margin | 58.3% | 56.5% | 64.5% | 60.6% |
| R&D Expenses | £127 | £563 | £931 | £861 |
| G&A Expenses | £84 | £70 | £37 | £29 |
| SG&A Expenses | £377 | £241 | £119 | £72 |
| Sales & Mktg Exp. | £293 | £171 | £81 | £44 |
| Other Operating Expenses | £3,028 | £2,784 | £2,035 | £2,094 |
| Operating Expenses | £3,532 | £3,588 | £3,085 | £3,027 |
| Operating Income | -£827 | -£2,905 | -£2,999 | -£2,982 |
| % Margin | -17.8% | -240.3% | -2,271.3% | -3,988.8% |
| Other Income/Exp. Net | £112 | -£44 | -£9 | -£10 |
| Pre-Tax Income | -£715 | -£2,949 | -£3,008 | -£2,992 |
| Tax Expense | -£19 | -£73 | -£173 | -£200 |
| Net Income | -£696 | -£2,876 | -£2,835 | -£2,793 |
| % Margin | -15% | -237.9% | -2,146.9% | -3,735.4% |
| EPS | -0.003 | -0.015 | -0.017 | -0.018 |
| % Growth | 79.9% | 10.5% | 3.4% | – |
| EPS Diluted | -0.003 | -0.015 | -0.017 | -0.018 |
| Weighted Avg Shares Out | 227,867 | 186,287 | 164,713 | 156,780 |
| Weighted Avg Shares Out Dil | 227,867 | 186,287 | 164,713 | 156,780 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £92 | £51 | £9 | £10 |
| Depreciation & Amortization | £427 | £176 | £44 | £30 |
| EBITDA | -£197 | -£2,722 | -£2,955 | -£2,952 |
| % Margin | -4.2% | -225.1% | -2,237.8% | -3,949.1% |